OBESITY IN 2010 The future of obesity medicine: where do we go from here?

被引：12
作者：
Wright, Suzanne M. [1 ]
Aronne, Louis J. [1 ]
机构：
[1] Weill Cornell Med Coll, Comprehens Weight Control Program, New York, NY 10065 USA
来源：
NATURE REVIEWS ENDOCRINOLOGY | 2011年 / 7卷 / 02期
关键词：
SIBUTRAMINE; TRIAL;
D O I：
10.1038/nrendo.2010.231
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：69 / 71
页数：3
相关论文
共 7 条
  • [1] Bays H, 2010, EXPERT REV CARDIOVAS, V8, P1777, DOI [10.1586/erc.10.125, 10.1586/ERC.10.125]
  • [2] Anorectics on trial: A half century of federal regulation of prescription appetite suppressants
    Colman, E
    [J]. ANNALS OF INTERNAL MEDICINE, 2005, 143 (05) : 380 - 385
  • [3] Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
    Greenway, Frank L.
    Fujioka, Ken
    Plodkowski, Raymond A.
    Mudaliar, Sunder
    Guttadauria, Maria
    Erickson, Janelle
    Kim, Dennis D.
    Dunayevich, Eduardo
    [J]. LANCET, 2010, 376 (9741) : 595 - 605
  • [4] Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
    James, W. Philip T.
    Caterson, Ian D.
    Coutinho, Walmir
    Finer, Nick
    Van Gaal, Luc F.
    Maggioni, Aldo P.
    Torp-Pedersen, Christian
    Sharma, Arya M.
    Shepherd, Gillian M.
    Rode, Richard A.
    Renz, Cheryl L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (10) : 905 - 917
  • [5] Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management.
    Smith, Steven R.
    Weissman, Neil J.
    Anderson, Christen M.
    Sanchez, Matilde
    Chuang, Emil
    Stubbe, Scott
    Bays, Harold
    Shanahan, William R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (03) : 245 - 256
  • [6] Sibutramine in cardiovascular disease: is SCOUT the new STORM on the horizon?
    von Haehling, Stephan
    Lainscak, Mitja
    Anker, Stefan D.
    [J]. EUROPEAN HEART JOURNAL, 2007, 28 (23) : 2830 - 2831
  • [7] VIVUS NEW LONG TERM
1